Determination of Midazolam and Its α-Hydroxy Metabolite in Human Plasma and Urine by High-Performance Liquid Chromatography

In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)

“…Metabolites were assayed by h.p.l.c., as described previously [17±19, 27,28]. The intraday and interday coef®cients of variation (CV) were <7% at relevant concentrations (n=6).…”

Simultaneous determination of midazolam and 1′‐hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry

“…Although LC-UV has been used for decades for the above purpose, these methodologies typically represent relatively poor sensitivity and low throughput, with a reported sensitivity of 1.0-100 ng/mL, sample size of up to 2.0 mL, and analysis cycle time of up to 18 min (Blackett et al, 1988;Carrillo et al, 1998;El Mahjoub and Staub, 2000;Ha et al, 1993;Johnson et al, 2002;Lee and Charles, 1996;Odou et al, 1997;Mastey et al, 1994;Portier et al, 1999;Puglisi et al, 1985;Sautou et al, 1991;ter Horst et al, 2003;van Brandt et al, 1997;Vletter et al, 1990;Yasui-Furukori et al, 2004). GC-MS methods appear to be more sensitive than HPLC-UV with a reported LLOQ of 20 pg/ mL for both midazolam and 1′-hydroxymidazolam when 1 mL of human plasma was used.…”

Simultaneous analysis of cytochrome P450 probes—dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma

“…DEX and its metabolites have previously been analyzed by HPLC coupled with fluorescence and positive-ion mass spectrometry [14,15]. MDZ and OHM have been analyzed by HPLC linked with UV detection and positive-ion mass spectrometry [16,17]. FLB and OHF have been analyzed previously by fluorescence subsequent to their chromatographic separation [11].…”